Cancer charities are demanding the number of staff in the NHS are increased “urgently” after new figures showed a rise in deaths from the disease last year.
A total of 16,105 deaths were caused by cancer in Scotland in 2017, up from 15,813 the previous year.
While the total number of cancer deaths reached its highest for 25 years, overall mortality rates from the disease have fallen by 10 percent in the last decade – going from 358 deaths per 100,000 people in 2007 to 321 deaths per 100,000 in 2017.
Oncimmune Plc (LON:ONC) is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company’s first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 155,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK, Europe & Asia. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT®-Liver launched in May 2018 and further tests are in development.
